Jacob Charles Andrews, | |
Prisma Health Children's Hospital Outpatient Center, 14 Medical Park, Ste 400, Columbia, SD 29203 | |
(803) 434-6155 | |
(803) 434-6979 |
Full Name | Jacob Charles Andrews |
---|---|
Gender | Male |
Speciality | Pediatrics |
Location | Prisma Health Children's Hospital Outpatient Center, Columbia, South Dakota |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861066367 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | LL83629 (South Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jacob Charles Andrews, Prisma Health Children's Hospital Outpatient Center, 14 Medical Park, Ste 400, Columbia, SD 29203 Ph: (803) 434-6155 | Jacob Charles Andrews, Prisma Health Children's Hospital Outpatient Center, 14 Medical Park, Ste 400, Columbia, SD 29203 Ph: (803) 434-6155 |
News Archive
e-Therapeutics plc announces that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company's anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.
A digital mammography system developed based on concepts originally tested at Massachusetts General Hospital (MGH) has been approved by the U.S. Food and Drug Administration.
Teamster members employed by the Philadelphia chapter of the American Red Cross are hard at work educating the public about the unfair labor conditions that they endure that could potentially put Philadelphia's blood supply at risk. More than 100 employees went on strike and set up a picket line yesterday when their issues were ignored by their employer.
Hospitality workers' exposure to harmful second hand smoke has fallen by 95 per cent since smokefree workplaces were introduced in England on 1 July 2007, according to new research revealed at the National Cancer Research Institute Conference in Birmingham on the three month anniversary of smokefree England.
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).
› Verified 9 days ago